Alendronate therapy substantially increases bone mineral density in pediatric patients with rheumatic diseases and secondary low bone mass.
Dr. Rolando Cimaz, at the Clinica Pediatrica, ICP, Milan, Italy, and colleagues evaluated changes in bone metabolism and disease activity markers in 45 pediatric patients with rheumatic diseases, aged five to 18 years, who were treated with alendronate for 12 months. There were 31 females and 14 males.
Among the variables they analyzed were demographic and anthropometric data, biochemical markers of bone metabolism, disease activity indexes, and bone mineral density values.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!